Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
    • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • COVID-19
    • Safety
    • Drug Reference Sheet
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    When the Provider Becomes the Patient: What I Learned From COVID-19
    COVID-19
    When the Provider Becomes the Patient: What I Learned From COVID-19
    June 24, 2022
    The Case of the Late Head and Neck Lymphedema
    Clinical practice
    The Case of the Late Head and Neck Lymphedema
    June 20, 2022
    Our Patients Give Us Peace in Unexpected Circumstances
    Oncology nurse pride
    Our Patients Give Us Peace in Unexpected Circumstances
    June 17, 2022
    Behind Our Masks, I See You, I Hear You
    COVID-19
    Behind Our Masks, I See You, I Hear You
    June 10, 2022
    Connect With Your Patients on a Human Level as Well as a Healthcare Level
    Oncology nurse-patient relationship
    Connect With Your Patients on a Human Level as Well as a Healthcare Level
    June 03, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
    • Home

    Author Content

    Oncology Drug Reference Sheet: Panitumumab (Vectibix®)
    Prescription medication

    Oncology Drug Reference Sheet: Panitumumab

    Approved in 2006 as monotherapy for the treatment of patients with EGFR-expressing metastatic colorectal cancer (mCRC) after disease progression following treatment, panitumumab has been a mainstay metastatic disease for more than a decade. In 2014, it received additional indication as first-line therapy for the treatment of patients with EGFR-expressing mCRC in combination with FOLFOX, but in 2017, use was narrowed to wild-type RAS (not mutated RAS). 

    March 23, 2020
    Psychosocial Support for Patients With Cancer During COVID-19
    COVID-19

    Psychosocial Support for Patients With Cancer During COVID-19

    When the COVID-19 novel coronavirus pandemic hit the United States, in a matter of days clinicians were scrambling to find novel ways to screen, triage, and provide telehealth interventions to protect patients with chronic conditions who are especially vulnerable to COVID-19. As nurses, we are accustomed to helping patients in crisis acclimate to a changing environment, process large amounts of information, and have their psychosocial needs met.

    March 17, 2020
    Oncology Drug Reference Sheet: Venetoclax
    Treatments

    Oncology Drug Reference Sheet: Venetoclax

    Venetoclax (Venclexta®) was approved by the U.S. Food and Drug Administration on May 15, 2019, for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as a single agent or in combination therapy. Previously, it had been approved in late 2018 for use in combination therapy for acute myeloid leukemia (AML) in older adults or those with significant comorbidities.

    August 27, 2019
    How ONS Is Supporting ONNs’ Professional Development
    Nurse navigator

    How ONS Is Supporting ONNs’ Professional Development

    Professional development needs of oncology nurse navigators (ONNs) have not been clearly identified, both for novice and more experienced navigators. Although some work has begun to define training for novice ONNs, most information about education for experienced ONNs comes from evaluation data and anecdotal reports.    

    May 28, 2019
    Joint Commission Focuses on Quality, Safety for 2019
    Safety

    Joint Commission Focuses on Quality, Safety for 2019

    As part of its ongoing work “to continuously improve health care for the public, in collaboration with other stakeholders, by evaluating healthcare organizations and inspiring them to excel in providing safe and effective care of the highest quality and value,” the Joint Commission hosts an annual Health Care Association Forum to educate associations about the commission’s latest initiatives and goals. Here are the outcomes that affect nursing practice in 2019.

    March 27, 2019
    Oncology Drug Reference Sheet: Glasdegib
    U.S. Food and Drug Administration (FDA)

    Oncology Drug Reference Sheet: Glasdegib

    In November 2018, the U.S. Food and Drug Administration (FDA) approved glasdegib (Daurismo™) for use in combination with low-dose cytarabine for treatment of patients with newly diagnosed acute myeloid leukemia who are not eligible for intensive chemotherapy. Data from clinical trials indicated that the regimen is safe for older adults and those with significant comorbidities, such as cardiac disease, poor performance status, or elevated serum creatinine.

    March 26, 2019
    Oncology Nurse Navigator
    Nurse navigator

    Updated Competencies Outline Oncology Nurse Navigator Role From Novice to Expert

    Based on the results of the oncology nurse navigator (ONN) role delineation survey and feedback from ONS membership, ONS evaluated and updated its ONN Core Competencies. Several significant changes were made.

    May 19, 2017
    Standards of Care
    Standards

    How Do I Move Standards of Care Into Practice?

    April 26, 2017

    To discuss the information in this article with other oncology nurses, visit the ONS Communities.

    To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

    Barbara Lubejko RN, MS
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap

  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
    • © Copyright 2022 Oncology Nursing Society
     
    Back to Top ▲